Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis by Betteridge, Zoe et al.
Concise report doi:10.1093/rheumatology/kez406
Identification of a novel autoantigen eukaryotic
initiation factor 3 associated with polymyositis
Zoe Betteridge1, Hector Chinoy 2,3, Jiri Vencovsky4, John Winer5,
Kiran Putchakayala6, Pauline Ho7, Ingrid Lundberg8, Katalin Danko9,
Robert Cooper10 and Neil McHugh 1
Abstract
Objectives. To describe the prevalence and clinical associations of autoantibodies to a novel autoantigen, eukaryotic
initiation factor 3 (eIF3), detected in idiopathic inflammatory myositis.
Methods. Sera or plasma from 678 PM patients were analysed for autoantigen specificity by radio-labelled protein
immunoprecipitation (IPP). Samples immunoprecipitating the same novel autoantigens were further analysed by indirect
immunofluorescence and IPP using pre-depleted cell extracts. The autoantigen was identified through a combination of
IPP and MALDI-TOF mass spectrometry, and confirmed using commercial antibodies and IPP-western blots. Additional
samples from patients with DM (668), DM-overlap (80), PM-overlap (191), systemic sclerosis (150), systemic lupus ery-
thematosus (200), Sjogren’s syndrome (40), rheumatoid arthritis (50) and healthy controls (150) were serotyped by IPP as
disease or healthy controls.
Results. IPP revealed a novel pattern in three PM patients (0.44%) that was not found in disease-specific or healthy
control sera. Indirect immunofluorescence demonstrated a fine cytoplasmic speckled pattern for all positive patients.
Mass spectrometry analysis of the protein complex identified the target autoantigen as eIF3, a cytoplasmic complex with
a role in the initiation of translation. Findings were confirmed by IPP-Western blotting. The three anti-eIF3-positive
patients had no history of malignancy or interstitial lung disease, and had a favourable response to treatment.
Conclusion. We report a novel autoantibody in 0.44% of PM patients directed against a cytoplasmic complex of
proteins identified as eIF3. Although our findings need further confirmation, anti-eIF3 appears to correlate with a good
prognosis and a favourable response to treatment.
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Rheumatology key messages
. Autoantibodies to eIF3 are present in 0.44% of adult PM patients.
. Autoantibodies to eIF3 may identify a form of polymyositis more responsive to immunosuppressive treatment.
Introduction
PM and DM are heterogeneous conditions characterized
by proximal muscle inflammation and weakness,
characteristic skin lesions and extramuscular features,
including interstitial lung disease (ILD) and cancer [1,
2]. There is strong evidence for a role of autoimmunity
in disease pathogenesis, with up to 70% of patients de-
veloping either myositis-specific or myositis-associated
autoantibodies (MSAs/MAAs) [3]. These autoantibodies
target specific proteins in the cell involved in gene tran-
scription, protein translocation and anti-viral responses.
The MSAs/MAAs help define more homogeneous clinical
subsets of myositis [4], thus aiding in the prediction of
disease course and treatment outcomes. The MAAs are
commonly found in patients with overlap features of
other connective tissue diseases, whereas MSAs are
found almost exclusively in PM and DM [4], and here
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correlate strongly with HLA genotypes and clinical
phenotypes [3].
In PM, the commonest MSAs are directed against
the cytoplasmic aminoacyl-transfer RNA synthetases
(ASAs), and are associated with a distinct phenotype
termed the anti-synthetase syndrome. To date, eight
ASAs have been fully described: Jo-1 is the most
common, occurring in 20% of myositis patients, with
the remaining ASAs (anti-PL12, anti-PL7, anti-OJ, anti-
EJ, anti-KS, anti-Zo and anti-Ha) each occurring in
<15% of PM patients [3]. Recently, the concept of
immune-mediated necrotizing myopathies has gained
recognition and together with the anti-synthetase
syndrome accounts for a majority of patients previously
classified as PM [5]. Autoantibodies associated with
immune-mediated necrotizing myopathies include anti-
signal recognition particle (SRP) [6] and anti-3-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCR) [7].
Herein, we describe the identification of a further myositis
autoantibody, anti-eukaryotic initiation factor 3 (eIF3) in
three patients with PM.
Methods
Patients and sera
Clinical data and serum/plasma samples from 678 adult
PM patients recruited to either the UKMYONET or
EuroMyositis cohorts were available for analysis [4]. All pa-
tients had probable or definite myositis according to the
Bohan and Peter diagnostic criteria [1, 2]. A standardized
pro forma was used throughout to collect demographic
and clinical case details [8]. The disease control population
consisted of 668 DM, 80 DM-overlap and 191 PM-overlap
patients [1, 2], 150 patients with systemic sclerosis [9], 200
patients with SLE [10], 40 patients with SS [11], 50 patients
with rheumatoid arthritis [12] and 100 otherwise healthy
controls. Written consent to participate and to provide bio-
logical samples was obtained from all subjects according
to the Declaration of Helsinki, under the local ethical com-
mittee regulations of each participating centre.
Protein immunoprecipitation using [35S]-methionine
10 ml sera or plasma was mixed with 2 mg protein-A-
Sepharose beads (Sigma, Gillingham, UK) in protein
immunoprecipitation (IPP) buffer (10 mM Tris-Cl pH 8.0,
500 mM NaCl, 0.1% v/v Igepal) at room temperature for
30 min. Beads were washed in IPP buffer prior to the add-
ition of 120ml [35S]-methionine labelled K562 cell extract
(prepared from 15  106 cells/ml). Samples were mixed at
4C for 2 h. Beads were washed in IPP buffer and TBS
buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl) before re-sus-
pension in Sample Buffer (Sigma, Gillingham, UK). After
heating, proteins were fractionated by 9% SDSPAGE
and analysed by autoradiography.
Indirect immunofluorescence
Indirect immunofluorescence was performed on HEp-2 cells
(Immunoconcepts, USA) using IgG fluorescein-labelled anti-
Human immunoglobulin (Sigma, Gillingham, UK).
IPP-Mass spectrometry (MS)
IPP was completed using 40 ml plasma, 2 mg protein-A-
Sepharose beads and 5 mM bis-(sulphosuccinimidyl)-
suberate (Perbio, UK). Beads were incubated in 4 ml
K562 cell extract (prepared from 28  106 cells/ml) for
4 h at 4C. Samples were re-suspended in Sample
Buffer. Proteins were heated, fractionated by 10%
SDSPAGE and stained with Imperial Protein Stain
(Perbio, UK). Unique bands were prepared for MALDI-
TOF MS at the University of the West of England.
Database matching using the ProteinLynx software
required peptide coverage of over 20% with matching of
the major theoretical and experimental peptide peaks.
IPP-blotting
IPP was completed using 40 ml plasma/serum (cases 1,
2 or 3, normal control serum or serum containing
known autoantibodies), 2 mg protein-A-Sepharose
beads and 5 mM bis-(sulphosuccinimidyl)-suberate
(Sigma, Gillingham, UK). Beads were incubated in
1 ml K562 cell extract (prepared from 28  106 cells/
ml) for 3 h at 4C. Samples were re-suspended in
sample buffer (Sigma, Gillingham, UK), heated and
fractionated by 10% SDSPAGE. Immunoprecipitates
were transferred to nitrocellulose and probed with
rabbit polyclonal anti-eIF3D antibody (1 : 500 dilution)
(Sigma, Gillingham, UK) for 90 min. Bands were de-
tected using alkaline phosphatase conjugated goat
anti-rabbit IgG (1 : 20000 dilution) (Sigma, Gillingham,
UK) antibody and BCIP/NBT liquid substrate solution
(Sigma, Gillingham, UK).
Results
Serotyping of PM patients
An IPP screen was completed on 678 PM patients. The
results showed the presence of the same IPP pattern in
three patients (cases 13). Samples from each patient
immunoprecipitated antigens at 25, 37, 39, 40, 42, 66,
95 and 110 kDa (Fig. 1A, Lanes 13), and these did not
correspond to any known autoantigen. None of these pa-
tients immunoprecipitated any other known myositis-spe-
cific or associated autoantigen. This novel pattern was not
seen in any immuno-precipitations using sera/plasma
from DM, DM-overlap or PM-overlap patients, or any of
the connective tissue disease or healthy controls.
Immunofluorescence of HEp2 cells using cases 13 re-
sulted in either a negative or weak, fine speckled ANA,
and a fine cytoplasmic speckle (data not shown). Overall
the prevalence of anti-eIF3 in PM was 0.4%.
Identification of the eIF3 antigens
Non-radiolabelled IPP demonstrated the presence of 37,
38, 40, 42, 66, 95 and 110 kDa bands using case 1 plasma
on two separate occasions (data not shown). MALDI-TOF
MS and Swiss-Prot analysis of the peptide fingerprints
from these bands corresponded to Eukaryotic Initiation
Factor 3 subunits (eIF3G, eIF3I, eIF3H, eIF3E/F eIF3L/D
eIF3B and eIF3A respectively).
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The autoantigen target was confirmed by IPP-blot using
commercial eIF3D protein. Immunoprecipitations were
completed using case 1, 2 or 3 plasma/serum, healthy
control serum or control samples containing known
autoantibodies. When the immunoprecipitates were trans-
ferred to nitrocellulose and probed with commercial anti-
eIF3D, strong bands, at the correct molecular weight for
eIF3D, were present with immunoprecipitates from cases
1, 2 and 3 but not from any of the disease or healthy con-
trol samples (Fig. 1B). Overall these results show that the
novel precipitation pattern seen with the three PM patients
is due to autoantibodies directed against eIF3.
Clinical data
Clinical analysis of the anti-eIF3 patients demonstrated two
of three patients to be female, with a median age at myo-
sitis onset for all three patients of 55 (range 5358). As well
as fulfilling Bohan and Peter criteria for PM, all three pa-
tients fulfilled EULAR-ACR classification criteria [13] of at
least probable idiopathic inflammatory myopathy, with no
evidence of rash or overlap features. None of the patients
had cancer-associated myositis or interstitial lung disease.
Other than mild Raynaud’s phenomenon in one patient
and arthritis in another, there were no features of anti-
synthetase syndrome. All anti-eIF3 positive patients had
highly elevated creatine kinase (CK) levels (ranging 1765
times the local cut-off values) and a significant pattern of
proximal muscle weakness at presentation, with no evi-
dence of distal muscle weakness. Of interest, two patients
had a prior history of cardiovascular disease (heart conduc-
tion defect and a history of myocardial infarction). Although
one of the three patients has a history of statin exposure,
there were no features of immune-mediated necrotising
myopathy on muscle biopsy (Table 1) and all three were
negative for anti-HMGCR autoantibodies (data not shown).
All of the anti-eIF3 patients were treated with prednisolone
with two patients also being given azathioprine (Table 1).
The small sample size precludes formal statistical analysis
of clinical associations. However, all three anti-eIF3 positive
patients responded well to treatment, being able to taper
off prednisolone completely and lacked severe organ com-
plications, suggesting it is feasible that anti-eIF3 autoanti-
bodies are a marker of a favourable outcome.
Discussion
MSAs identify homogeneous clinical subsets within the
IIM spectrum [4]. The identification of a novel MSA is
FIG. 1 Protein immunoprecipitation and immunoprecipitation/blot using anti-EIF3 sera from three cases and controls
(A) Autoradiogram of 10% SDSPAGE of immunoprecipitates using case 13 serum/plasma (lanes 13), healthy control
serum (lane 4), control serum containing autoantibodies to Ro-60, La and PMScl (lane 5), PL7, PL12 and Zo (lane 6) and
snRNP and Jo-1 (lane 7) using [35S] methionine-labelled cell extract. Arrows indicate apparent molecular weights of
autoantigens immunoprecipitated by some or all case samples. (B) IPP-blot of eIF3 autoantigens. Antigens were
immunoprecipitated using case sera/plasma or controls. Lanes 1, 6 and 11: molecular weight marker; lane 2: case 1
plasma; lane 3: case 2 plasma; lanes 4 and 5: IPP eIF3 negative PM serum; lane 7: healthy control serum; lane 8: serum
containing anti-PMScl, La and Ro-60; lane 9: serum containing anti-snRNP and anti-Jo-1; lane 10: serum containing anti-
PL7 and anti-PL12; lane 12: case 3 serum. Immunoprecipitates were separated on SDSPAGE and transferred to a
nitrocellulose membrane. Membranes were probed with commercial anti-eIF3D. Bands corresponding to eIF3D and the
molecular weight markers are indicated.
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therefore of interest, and may define a further clinical sub-
group that predicts the nature of subsequent disease.
Herein we describe the first report of autoantibodies dir-
ected against eIF3 in three patients with clinical features
of PM. Anti-eIF3 autoantibodies are rare but occur at a
similar frequency, in this predominantly Caucasian cohort,
as a number of the non-Jo-1 ASAs. None of our eIF3 pa-
tients had features of CTD overlap, cancer-associated
myositis or interstitial lung disease, and all demonstrated
a good response to treatment. Therefore, patients with
this autoantibody appear to have a favourable prognosis
compared with some other myositis subsets, although
larger numbers are needed to confirm this notion.
Furthermore, the combination of clinical features towards
a milder end of the myositis disease spectrum could indi-
cate that anti-eIF3 patients are less likely to be referred to
myositis clinics, and thus may be under-represented in
myositis cohort studies.
As demonstrated by the IPP results, mammalian eIF3 is
a multi-subunit complex with an apparent molecular
weight of 650 kDa, consisting of 13 non-identical sub-
units that range in size from 25 to 170 kDa [14]. Although
our study has demonstrated the presence of autoantibo-
dies to eIF3 in PM patients, it remains to be determined
whether these autoantibodies are targeted towards the
entire complex or a particular subunit. The eIF3 complex
is mainly located in the cytoplasm, which is consistent
with the cytoplasmic staining pattern seen on indirect im-
munofluorescence with all anti-eIF3 positive sera.
Mammalian eIF3 has been reported to have multiple func-
tions, but primarily acts to ensure assembly of the 43S
pre-initiation complex by direct recruitment of the 40S
ribosomal subunit [15]; therefore, along with the other
PM associated autoantigens (SRP and the ASAs), eIF3
has an important role in protein translation.
Of interest, studies have shown a further role for eIF3F in
skeletal muscle regulation. Skeletal muscle atrophy is char-
acterized by a decrease in the size of pre-existing muscle
fibres and is seen in a number of physiological and patho-
logical settings including myositis. In several models of
skeletal muscle atrophy, the E3 ubiquitin ligase (Atrogin/
MAFbx) is up-regulated. Increased levels of the ligase
target eIF3F for ubiquitination and degradation by the pro-
teosome, leading to rapid atrophy [16, 17]. Furthermore, in
TABLE 1 Clinical manifestations of anti-eIF3 positive patients and comparison with the anti-eIF3 negative PM cohort
Case 1 Case 2 Case 3 EIF3 negative
AOO
58 53 55
Median = 55 (IQR:
42.0064.00)
Median = 55 (IQR: 54.0056.50)
Gender Female Female Male 213 M / 455 F (32:
68% )
CAM No No No 49/654 (7.5%)
ILD No No No 197/655 (30.1%)
Raised CK (8815 U/L) (5940 U/L) (2754a U/L) 598/631 (94.8%)
Proximal
weakness
Yes Yes Yes 494/511 (96.7%)
Weight loss No Yes No Data not collected
Arthritis No No Yes 269/632 (42.6%)
EMG Positive Positive Negative 309/420 (73.6%)
Muscle MRI Widespread oedema most
marked within adductors
and rectus femori
Patchy high signal on STIR
sequences throughout
thigh muscles
Diffuse strong oedema
thigh muscles and peri-
fascial spaces
Muscle biopsy Positive  further details
not available
Scant endomysial inflam-
mation. Perivascular B
lymphocytes. HLA Class
I expression on regener-
ating fibresb
Large predominantly peri-
mysial inflammatory in-
filtrate also endomysial.
HLA Class I over-ex-
pression on muscle
fibres
Data not collected
Raynaud’s
phenomenon
No No Mild 203/487 (41.6%)
Cardiac
involvement
None Heart conduction defect Myocardial Infarction (age
47)
34/400 (8.5%)
Treatment Prednisolone and
azathioprine
1 mg/kg prednisolone and
azathioprine
40 mg/day prednisolone Data not collected
Response to
treatment
Good: prednisolone dis-
continued after 1 yr
Good: prednisolone dis-
continued. Sustained re-
mission on 50 mg
azathioprine
Good: prednisolone dis-
continued after 2 yr
Data not collected
aCK of 46 mkat/l converted to units/l using www.amamanualofstyle.com/page/si-conversion-calculator. bMuscle biopsy taken
two weeks after commencement of steroids. AOO: age of onset; CAM: cancer associated myositis; CK: creatine kinase; F:
Female; ILD: interstitial lung disease; IQR: interquartile range; M: Male; STIR, short-TI inversion recovery.
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mouse models, eIF3f depletion impedes embryonic devel-
opment, reduces adult skeletal muscle mass and amplifies
muscle loss during disuse [18]. All of the anti-eIF3 positive
patients identified in this cohort had clinical symptoms of
muscle weakness and whilst no details regarding muscle
atrophy was available for our patients, these findings indi-
cate a potential pathogenic link between the role of eIF3 in
skeletal muscle atrophy and the presence of eIF3 autoan-
tibodies. It would be of interest to investigate whether the
anti-eIF3 positive patients have evidence of muscle atrophy
and whether the eIF3F subunit is specifically targeted by
the anti-eIF3 autoantibodies.
In conclusion, we have described a novel autoantibody,
anti-eIF3 autoantibody, in a small number of PM patients
who are negative for all other MSA/MAAs. Whilst the num-
bers are small, the presence of the autoantibody appears
to associate with a favourable prognosis, with an absence
of malignancy and ILD, and a good response to immuno-
suppression. The eIF3 protein shares similar features to
other PM autoantigens, in that it plays a key role in protein
synthesis. Additionally, the autoantibody targeting of a
protein complex involved in myotube integrity may pro-
vide further insight into the pathogenesis of myositis.
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